Drug Type Small molecule drug |
Synonyms AAE 581, AAE-581 |
Target |
Mechanism CTSK inhibitors(Cathepsin K inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H33N5O2 |
InChIKeyLLCRBOWRJOUJAE-UHFFFAOYSA-N |
CAS Registry354813-19-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 2 | US | 01 Dec 2004 | |
Osteoarthritis, Knee | Phase 2 | DE | 01 Dec 2004 | |
Osteoporosis | Phase 2 | - | 01 Feb 2004 | |
Osteoporosis, Postmenopausal | Phase 2 | US | - | - |
Osteoporosis, Postmenopausal | Phase 2 | JP | - | - |
Osteoporosis, Postmenopausal | Phase 2 | CA | - | - |
Osteoporosis, Postmenopausal | Phase 2 | - | - | - |
Glaucoma, Open-Angle | Preclinical | US | 01 Jun 2021 |